Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pain
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pain
    TopAbstracts in Pain 11/05/2009 - (DGNews)
    TopAbstracts in Pain 10/29/2009 - (DGNews)
    Subcutaneous Methylnaltrexone Shows Efficacy for Opioid-Induced Constipation: Presented at ACG - (DGDispatch)
    Intravitreal Bevacizumab Provides Pain Relief, Improves Surgical Results in Patients With Neovascular Glaucoma: Presented at AAO-PAAO - (DGDispatch)
    Ketorolac Safely Controls Postoperative Pain in Children: Presented at AAP - (DGDispatch)

    News archive

     Recent webcasts/CME - Pain
    • Practical Considerations in Management of Chronic Pain
    • Overview of Chronic Pain: Practical Definitions and Characteristics
    • An Interdisciplinary Approach to Chronic Pain: Improving Outcomes by Overcoming Therapeutic Barriers
    • Revisiting Pain Management in Cancer Patients: Breakthrough Pain and its Treatments
      A Guide to Advances in Pain Management: A Synopsis of Roundtable Discussions

      Webcasts/CME archive

       Recent cases - Pain
        A Painful Red Eye
        A Patient with Osteoarthritis and Cardiovascular Disease Presenting with Bilateral Hip Pain: A Case Report
        Abdominal Pain Due to a Lost Guidewire: A Case Report
        Acute Abdominal Pain in a Patient Receiving Enoxaparin
        Non-Invasive Neurosensory Testing Used to Diagnose and Confirm Successful Surgical Management of Lower Extremity Deep Distal Posterior Compartment Syndrome

        Cases archive
          




        my personal edition > pain > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Methylnaltrexone May Alleviate Opioid-Induced Constipation in Severely Ill Patients: Presented at AAPM

        By Jerry Ingram

        NEW ORLEANS, LA -- February 12, 2007 -- Methylnaltrexone may alleviate the constipation faced by severely ill patients who rely on opioids for pain relief, suggest results from 2 phase 3 trials presented here at the American Academy of Pain Medicine 23rd Annual Meeting (AAPM).

        "The bottom line is that it seems that [methylnaltrexone] does reverse the constipating effect of the opioids in many patients," stated the study's lead investigator Jay Thomas, MD, clinical medical director, San Diego Hospice, San Diego, California.

        It's well tolerated and has a predictable onset of action and may be a big addition to help decrease the number of laxatives that patients have to take and decrease side effects, Dr. Thomas said in a presentation on February 9th.

        "The side effects of opioids among patients who have advanced illness cause a lot of morbidity as well as a lot of cost to the system. The treatments we have now often don't work that well and patients need to take many of them," he explained.

        Dr. Thomas and his team examined the results of 2 multicenter, randomized, double-blind, placebo-controlled trials that compared methylnaltrexone with placebo.

        In their first trial, investigators assigned 301 patients to methylnaltrexone 0.15 or 0.30 mg/kg or to placebo. In the second trial, they assigned 133 patients to receive either methylnaltrexone 0.15mg/kg or placebo for 2 weeks. All patients had a life expectancy of less than 6 months, no laxation for 48 hours, and were receiving opioids along with stable doses of laxatives.

        Researchers set their primary efficacy endpoint as laxation within 4 hours after a first dose of methylnaltrexone. In addition, they examined endpoints of laxation within 24 hours, laxation occurring within 4 hours of at least 2 of the first 4 doses of the trial medication.

        Results showed that patients receiving methylnaltrexone experienced improved laxation (62% in the first study and 48.4% in the second study) within the first 4 hours of administration, the researchers reported.

        They noted that the median time to laxation was significantly less for those in the methylnaltrexone group -- 70 minutes versus 24 hours for those in the placebo group (P < .0001).

        Dr. Thomas said he anticipates that methylnaltrexone will be considered for marketing approval by the US Food and Drug Administration next year.


        [Presentation title: Phase III Results From Two Multi-Center Randomized Double-Blind Placebo-Controlled Trials of Methylnaltrexone for Opioid-Induced Constipation (OIC) in Patients With Advanced Illness (AI). Abstract 137]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send